Frederick S Buckner

List of Publications by Year
in descending order

131	6,339	57758 44	79698 73
papers	citations	h-index	g-index

140	140	140	6905
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Synthesis and Structureâ"Activity Relationships of Imidazopyridine/Pyrimidineâ€•and Furopyridineâ€Based Antiâ€infective Agents against Trypanosomiases. ChemMedChem, 2021, 16, 966-975.	3.2	16
2	The Tryp and the Pendulum. EBioMedicine, 2021, 64, 103188.	6.1	0
3	Early Stages of Drug Discovery in an Academic Institution and Involvement of Pharma for Advancing Promising Leads. ACS Infectious Diseases, 2021, 7, 1874-1876.	3.8	1
4	Spontaneous Selection of Cryptosporidium Drug Resistance in a Calf Model of Infection. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	12
5	Case Report: Miltefosine Failure and Spontaneous Resolution of Cutaneous Leishmaniasis braziliensis. American Journal of Tropical Medicine and Hygiene, 2021, 105, 142-143.	1.4	1
6	A new chemotype with promise against Trypanosoma cruzi. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 126778.	2.2	1
7	Setting Our Sights on Infectious Diseases. ACS Infectious Diseases, 2020, 6, 3-13.	3.8	17
8	Structure-guided discovery of selective methionyl-tRNA synthetase inhibitors with potent activity against Trypanosoma brucei. RSC Medicinal Chemistry, 2020, 11, 885-895.	3.9	12
9	Methionyl-tRNA synthetase inhibitor has potent in vivo activity in a novel Giardia lamblia luciferase murine infection model. Journal of Antimicrobial Chemotherapy, 2020, 75, 1218-1227.	3.0	12
10	Phenotypic Drug Discovery for Human African Trypanosomiasis: A Powerful Approach. Tropical Medicine and Infectious Disease, 2020, 5, 23.	2.3	6
11	Clinical Features and Outcomes of 105 Hospitalized Patients With COVID-19 in Seattle, Washington. Clinical Infectious Diseases, 2020, 71, 2167-2173.	5.8	95
12	A 71-year-old man with recurrent pulmonary mycobacterial avium complex infections and lymphopenia. Allergy and Asthma Proceedings, 2020, 41, 66-69.	2.2	1
13	Bioactivity of Farnesyltransferase Inhibitors Against Entamoeba histolytica and Schistosoma mansoni. Frontiers in Cellular and Infection Microbiology, 2019, 9, 180.	3.9	12
14	Optimization of Methionyl tRNA-Synthetase Inhibitors for Treatment of Cryptosporidium Infection. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	37
15	Triazolopyrimidines and Imidazopyridines: Structureâ€"Activity Relationships and in Vivo Efficacy for Trypanosomiasis. ACS Medicinal Chemistry Letters, 2019, 10, 105-110.	2.8	19
16	The crystal structure of the drug targetMycobacterium tuberculosismethionyl-tRNA synthetase in complex with a catalytic intermediate. Acta Crystallographica Section F, Structural Biology Communications, 2018, 74, 245-254.	0.8	10
17	From Cells to Mice to Target: Characterization of NEU-1053 (SB-443342) and Its Analogues for Treatment of Human African Trypanosomiasis. ACS Infectious Diseases, 2017, 3, 225-236.	3.8	19
18	Leishmania donovani tyrosyl-tRNA synthetase structure in complex with a tyrosyl adenylate analog and comparisons with human and protozoan counterparts. Biochimie, 2017, 138, 124-136.	2.6	13

#	Article	IF	Citations
19	Optimization of a binding fragment targeting the â€œenlarged methionine pocketâ€•leads to potent Trypanosoma brucei methionyl-tRNA synthetase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 2702-2707.	2.2	14
20	Urea Derivatives of 2-Aryl-benzothiazol-5-amines: A New Class of Potential Drugs for Human African Trypanosomiasis. Journal of Medicinal Chemistry, 2017, 60, 957-971.	6.4	47
21	Development of Methionyl-tRNA Synthetase Inhibitors as Antibiotics for Gram-Positive Bacterial Infections. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	25
22	1-Benzyl-3-aryl-2-thiohydantoin Derivatives as New Anti-Trypanosoma brucei Agents: SAR and in Vivo Efficacy. ACS Medicinal Chemistry Letters, 2017, 8, 886-891.	2.8	27
23	New Class of Antitrypanosomal Agents Based on Imidazopyridines. ACS Medicinal Chemistry Letters, 2017, 8, 766-770.	2.8	21
24	Discovery of N-(2-aminoethyl)-N-benzyloxyphenyl benzamides: New potent Trypanosoma brucei inhibitors. Bioorganic and Medicinal Chemistry, 2017, 25, 1571-1584.	3.0	10
25	Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness. Nature, 2016, 537, 229-233.	27.8	325
26	Structure-guided design of novel Trypanosoma brucei Methionyl-tRNA synthetase inhibitors. European Journal of Medicinal Chemistry, 2016, 124, 1081-1092.	5.5	25
27	5-Fluoroimidazo[4,5-b]pyridine Is a Privileged Fragment That Conveys Bioavailability to Potent Trypanosomal Methionyl-tRNA Synthetase Inhibitors. ACS Infectious Diseases, 2016, 2, 399-404.	3.8	28
28	Brucella melitensis Methionyl-tRNA-Synthetase (MetRS), a Potential Drug Target for Brucellosis. PLoS ONE, 2016, 11, e0160350.	2.5	21
29	A binding hotspot inTrypanosoma cruzihistidyl-tRNA synthetase revealed by fragment-based crystallographic cocktail screens. Acta Crystallographica Section D: Biological Crystallography, 2015, 71, 1684-1698.	2.5	19
30	Inhibitors of Methionyl-tRNA Synthetase Have Potent Activity against Giardia intestinalis Trophozoites. Antimicrobial Agents and Chemotherapy, 2015, 59, 7128-7131.	3.2	21
31	Identification of Potent Inhibitors of the Trypanosoma brucei Methionyl-tRNA Synthetase via High-Throughput Orthogonal Screening. Journal of Biomolecular Screening, 2015, 20, 122-130.	2.6	35
32	Structures of Trypanosoma brucei Methionyl-tRNA Synthetase with Urea-Based Inhibitors Provide Guidance for Drug Design against Sleeping Sickness. PLoS Neglected Tropical Diseases, 2014, 8, e2775.	3.0	37
33	Synergy Testing of FDA-Approved Drugs Identifies Potent Drug Combinations against Trypanosoma cruzi. PLoS Neglected Tropical Diseases, 2014, 8, e2977.	3.0	80
34	Substituted 2-Phenylimidazopyridines: A New Class of Drug Leads for Human African Trypanosomiasis. Journal of Medicinal Chemistry, 2014, 57, 828-835.	6.4	67
35	Recent Developments in Drug Discovery for Leishmaniasis and Human African Trypanosomiasis. Chemical Reviews, 2014, 114, 11305-11347.	47.7	274
36	Dialkylimidazole inhibitors of Trypanosoma cruzi sterol 14Î±-demethylase as anti-Chagas disease agents. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 6492-6499.	2.2	11

#	Article	IF	Citations
37	Crystal structures of Plasmodium falciparum cytosolic tryptophanyl-tRNA synthetase and its potential as a target for structure-guided drug design. Molecular and Biochemical Parasitology, 2013, 189, 26-32.	1.1	27
38	Induced Resistance to Methionyl-tRNA Synthetase Inhibitors in Trypanosoma brucei Is Due to Overexpression of the Target. Antimicrobial Agents and Chemotherapy, 2013, 57, 3021-3028.	3.2	19
39	Pharmacological Characterization, Structural Studies, andIn VivoActivities of Anti-Chagas Disease Lead Compounds Derived from Tipifarnib. Antimicrobial Agents and Chemotherapy, 2012, 56, 4914-4921.	3.2	50
40	Structure of the prolyl-tRNA synthetase from the eukaryotic pathogenGiardia lamblia. Acta Crystallographica Section D: Biological Crystallography, 2012, 68, 1194-1200.	2.5	9
41	Recent developments in sterol 14-demethylase inhibitors for Chagas disease. International Journal for Parasitology: Drugs and Drug Resistance, 2012, 2, 236-242.	3.4	85
42	Recent highlights in anti-protozoan drug development and resistance research. International Journal for Parasitology: Drugs and Drug Resistance, 2012, 2, 230-235.	3.4	22
43	Urea-Based Inhibitors of Trypanosoma brucei Methionyl-tRNA Synthetase: Selectivity and in Vivo Characterization. Journal of Medicinal Chemistry, 2012, 55, 6342-6351.	6.4	60
44	Bioisosteric Transformations and Permutations in the Triazolopyrimidine Scaffold To Identify the Minimum Pharmacophore Required for Inhibitory Activity against Plasmodium falciparum Dihydroorotate Dehydrogenase. Journal of Medicinal Chemistry, 2012, 55, 7425-7436.	6.4	67
45	Distinct States of Methionyl-tRNA Synthetase Indicate Inhibitor Binding by Conformational Selection. Structure, 2012, 20, 1681-1691.	3.3	69
46	Experimental Chemotherapy and Approaches to Drug Discovery for Trypanosoma cruzi Infection. Advances in Parasitology, 2011, 75, 89-119.	3.2	25
47	Structure of Leishmania major methionyl-tRNA synthetase in complex with intermediate products methionyladenylate and pyrophosphate. Biochimie, 2011, 93, 570-582.	2.6	50
48	Lead Optimization of Aryl and Aralkyl Amine-Based Triazolopyrimidine Inhibitors of Plasmodium falciparum Dihydroorotate Dehydrogenase with Antimalarial Activity in Mice. Journal of Medicinal Chemistry, 2011, 54, 3935-3949.	6.4	156
49	The Double-Length Tyrosyl-tRNA Synthetase from the Eukaryote Leishmania major Forms an Intrinsically Asymmetric Pseudo-Dimer. Journal of Molecular Biology, 2011, 409, 159-176.	4.2	40
50	Crystal structures of three protozoan homologs of tryptophanyl-tRNA synthetase. Molecular and Biochemical Parasitology, 2011, 177, 20-28.	1.1	16
51	Screening a fragment cocktail library using ultrafiltration. Analytical and Bioanalytical Chemistry, 2011, 401, 1585-1591.	3.7	9
52	Selective Inhibitors of Methionyl-tRNA Synthetase Have Potent Activity against Trypanosoma brucei Infection in Mice. Antimicrobial Agents and Chemotherapy, 2011, 55, 1982-1989.	3.2	75
53	An Essential Farnesylated Kinesin in Trypanosoma brucei. PLoS ONE, 2011, 6, e26508.	2.5	4
54	Advances in Chagas disease drug development: 2009â€“2010. Current Opinion in Infectious Diseases, 2010, 23, 609-616.	3.1	60

#	Article	IF	Citations
55	Prediction of protein crystallization outcome using a hybrid method. Journal of Structural Biology, 2010, 171, 64-73.	2.8	17
56	The structure of tryptophanyl-tRNA synthetase from Giardia lamblia reveals divergence from eukaryotic homologs. Journal of Structural Biology, 2010, 171, 238-243.	2.8	12
57	The Crystal Structure and Activity of a Putative Trypanosomal Nucleoside Phosphorylase Reveal It to be a Homodimeric Uridine Phosphorylase. Journal of Molecular Biology, 2010, 396, 1244-1259.	4.2	16
58	Crystal Structures of Trypanosomal Histidyl-tRNA Synthetase Illuminate Differences between Eukaryotic and Prokaryotic Homologs. Journal of Molecular Biology, 2010, 397, 481-494.	4.2	37
59	Toxoplasma gondii calcium-dependent protein kinase 1 is a target for selective kinase inhibitors. Nature Structural and Molecular Biology, 2010, 17, 602-607.	8.2	172
60	Delusional parasitosis: six-year experience with 23 consecutive cases at an academic medical center. International Journal of Infectious Diseases, 2010, 14, e317-e321.	3.3	34
61	Crystal structure of the aspartyl-tRNA synthetase from Entamoeba histolytica. Molecular and Biochemical Parasitology, 2010, 169, 95-100.	1.1	14
62	Second Generation Analogues of the Cancer Drug Clinical Candidate Tipifarnib for Anti-Chagas Disease Drug Discovery. Journal of Medicinal Chemistry, 2010, 53, 3887-3898.	6.4	107
63	Buffer Optimization of Thermal Melt Assays of Plasmodium Proteins for Detection of Small-Molecule Ligands. Journal of Biomolecular Screening, 2009, 14, 700-707.	2.6	42
64	Fragment-Based Cocktail Crystallography by the Medical Structural Genomics of Pathogenic Protozoa Consortium. Current Topics in Medicinal Chemistry, 2009, 9, 1678-1687.	2.1	36
65	Heterologous expression of L. major proteins in S. cerevisiae: a test of solubility, purity, and gene recoding. Journal of Structural and Functional Genomics, 2009, 10, 233-247.	1.2	43
66	Isoquinoline-based analogs of the cancer drug clinical candidate tipifarnib as anti-Trypanosoma cruzi agents. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 6582-6584.	2.2	17
67	Rational Modification of a Candidate Cancer Drug for Use Against Chagas Disease. Journal of Medicinal Chemistry, 2009, 52, 1639-1647.	6.4	150
68	Structurally Simple Inhibitors of Lanosterol 14Î±-Demethylase Are Efficacious In a Rodent Model of Acute Chagas Disease. Journal of Medicinal Chemistry, 2009, 52, 3703-3715.	6.4	38
69	Identification of a Metabolically Stable Triazolopyrimidine-Based Dihydroorotate Dehydrogenase Inhibitor with Antimalarial Activity in Mice. Journal of Medicinal Chemistry, 2009, 52, 1864-1872.	6.4	228
70	Altered sterol profile induced in Leishmania amazonensis by a natural dihydroxymethoxylated chalcone. Journal of Antimicrobial Chemotherapy, 2009, 63, 469-472.	3.0	39
71	Identification of Three Classes of Heteroaromatic Compounds with Activity against Intracellular Trypanosoma cruzi by Chemical Library Screening. PLoS Neglected Tropical Diseases, 2009, 3, e384.	3.0	63
72	High-throughput screening of amastigotes of Leishmania donovani clinical isolates against drugs using a colorimetric beta-lactamase assay. Indian Journal of Experimental Biology, 2009, 47, 475-9.	0.0	19

#	Article	IF	Citations
73	Structure of aTrypanosoma bruceiÎ±/Î²-hydrolase fold protein with unknown function. Acta Crystallographica Section F: Structural Biology Communications, 2008, 64, 474-478.	0.7	5
74	Genomic-scale prioritization of drug targets: the TDR Targets database. Nature Reviews Drug Discovery, 2008, 7, 900-907.	46.4	282
75	Characterization of Trypanosoma brucei dihydroorotate dehydrogenase as a possible drug target; structural, kinetic and RNAi studies. Molecular Microbiology, 2008, 68, 37-50.	2.5	73
76	Protein geranylgeranyltransferase-I of Trypanosoma cruzi. Molecular and Biochemical Parasitology, 2008, 157, 32-43.	1.1	14
77	Sterol 14-Demethylase Inhibitors for Trypanosoma cruzi Infections. Advances in Experimental Medicine and Biology, 2008, 625, 61-80.	1.6	47
78	Potent, Plasmodium-Selective Farnesyltransferase Inhibitors That Arrest the Growth of Malaria Parasites: Structureâ^'Activity Relationships of Ethylenediamine-Analogue Scaffolds and Homology Model Validation. Journal of Medicinal Chemistry, 2008, 51, 5176-5197.	6.4	33
79	Structures of Substrate- and Inhibitor-Bound Adenosine Deaminase from a Human Malaria Parasite Show a Dramatic Conformational Change and Shed Light on Drug Selectivity. Journal of Molecular Biology, 2008, 381, 975-988.	4.2	33
80	Glycogen Synthase Kinase 3 Is a Potential Drug Target for African Trypanosomiasis Therapy. Antimicrobial Agents and Chemotherapy, 2008, 52, 3710-3717.	3.2	86
81	Structural Genomics of Pathogenic Protozoa: an Overview. Methods in Molecular Biology, 2008, 426, 497-513.	0.9	38
82	Efficacy, Pharmacokinetics, and Metabolism of Tetrahydroquinoline Inhibitors of Plasmodium falciparum Protein Farnesyltransferase. Antimicrobial Agents and Chemotherapy, 2007, 51, 3659-3671.	3.2	40
83	Second Generation Tetrahydroquinoline-Based Protein Farnesyltransferase Inhibitors as Antimalarials. Journal of Medicinal Chemistry, 2007, 50, 4585-4605.	6.4	66
84	The structure ofPlasmodium vivaxphosphatidylethanolamine-binding protein suggests a functional motif containing a left-handed helix. Acta Crystallographica Section F: Structural Biology Communications, 2007, 63, 178-182.	0.7	5
85	C-terminal proteolysis of prenylated proteins in trypanosomatids and RNA interference of enzymes required for the post-translational processing pathway of farnesylated proteins. Molecular and Biochemical Parasitology, 2007, 153, 115-124.	1.1	25
86	Structurally Simple, Potent, Plasmodium Selective Farnesyltransferase Inhibitors That Arrest the Growth of Malaria Parasites. Journal of Medicinal Chemistry, 2006, 49, 5710-5727.	6.4	36
87	Thematic review series: Lipid Posttranslational Modifications. Fighting parasitic disease by blocking protein farnesylation. Journal of Lipid Research, 2006, 47, 233-240.	4.2	104
88	Using Fragment Cocktail Crystallography To Assist Inhibitor Design ofTrypanosoma bruceiNucleoside 2-Deoxyribosyltransferaseâ€. Journal of Medicinal Chemistry, 2006, 49, 5939-5946.	6.4	66
89	Structure of the conserved hypothetical protein MAL13P1.257 fromPlasmodium falciparum. Acta Crystallographica Section F: Structural Biology Communications, 2006, 62, 180-185.	0.7	9
90	Structure of ribose 5-phosphate isomerase fromPlasmodium falciparum. Acta Crystallographica Section F: Structural Biology Communications, 2006, 62, 427-431.	0.7	13

#	Article	IF	Citations
91	Confirmation of Chagas' cardiomyopathy following heart transplantation. Heart and Vessels, 2006, 21, 325-327.	1.2	4
92	Heterologous expression of proteins from Plasmodium falciparum: Results from 1000 genes. Molecular and Biochemical Parasitology, 2006, 148, 144-160.	1.1	173
93	Protein Farnesyltransferase Inhibitors Exhibit Potent Antimalarial Activity. Journal of Medicinal Chemistry, 2005, 48, 3704-3713.	6.4	170
94	Leishmania inactivation in human pheresis platelets by a psoralen (amotosalen HCl) and long-wavelength ultraviolet irradiation. Transfusion, 2005, 45, 1459-1463.	1.6	52
95	Differential drug binding by the highly conserved Plasmodium falciparum thymidylate synthase. Molecular and Biochemical Parasitology, 2005, 143, 121-124.	1.1	7
96	Upregulation of sterol C14-demethylase expression in Trypanosoma cruzi treated with sterol biosynthesis inhibitors. Molecular and Biochemical Parasitology, 2005, 144, 68-75.	1.1	24
97	Structurally Simple Farnesyltransferase Inhibitors Arrest the Growth of Malaria Parasites. Angewandte Chemie - International Edition, 2005, 44, 4903-4906.	13.8	37
98	Crystal structure of glyceraldehyde-3-phosphate dehydrogenase from Plasmodium falciparum at 2.25 Ã... resolution reveals intriguing extra electron density in the active site. Proteins: Structure, Function and Bioinformatics, 2005, 62, 570-577.	2.6	34
99	The Protein Farnesyltransferase Inhibitor Tipifarnib as a New Lead for the Development of Drugs against Chagas Disease. Journal of Medicinal Chemistry, 2005, 48, 5415-5418.	6.4	83
100	COLORIMETRIC ASSAY FOR SCREENING COMPOUNDS AGAINST LEISHMANIA AMASTIGOTES GROWN IN MACROPHAGES. American Journal of Tropical Medicine and Hygiene, 2005, 72, 600-605.	1.4	49
101	Colorimetric assay for screening compounds against Leishmania amastigotes grown in macrophages. American Journal of Tropical Medicine and Hygiene, 2005, 72, 600-5.	1.4	27
102	Protein farnesyl transferase inhibitors for the treatment of malaria and African trypanosomiasis. Current Opinion in Investigational Drugs, 2005, 6, 791-7.	2.3	33
103	In vitro and in vivo antimalarial activity of peptidomimetic protein farnesyltransferase inhibitors with improved membrane permeability. Bioorganic and Medicinal Chemistry, 2004, 12, 6517-6526.	3.0	45
104	Design and Synthesis of Peptidomimetic Protein Farnesyltransferase Inhibitors as Anti-Trypanosoma brucei Agents. Journal of Medicinal Chemistry, 2004, 47, 432-445.	6.4	49
105	Cloning and analysis of Trypanosoma cruzi lanosterol 14Î±-demethylase. Molecular and Biochemical Parasitology, 2003, 132, 75-81.	1.1	18
106	Protein farnesyl and N-myristoyl transferases: piggy-back medicinal chemistry targets for the development of antitrypanosomatid and antimalarial therapeutics. Molecular and Biochemical Parasitology, 2003, 126, 155-163.	1.1	126
107	Oxidosqualene Cyclase Inhibitors as Antimicrobial Agents. Journal of Medicinal Chemistry, 2003, 46, 4240-4243.	6.4	33
108	A class of sterol 14-demethylase inhibitors as anti-Trypanosoma cruzi agents. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 15149-15153.	7.1	65

#	Article	IF	Citations
109	Trypanosoma brucei prenylated-protein carboxyl methyltransferase prefers farnesylated substrates. Biochemical Journal, 2002, 367, 809-816.	3.7	9
110	Cloning, heterologous expression, and substrate specificities of protein farnesyltransferases from Trypanosoma cruzi and Leishmania major. Molecular and Biochemical Parasitology, 2002, 122, 181-188.	1.1	53
111	Isothiazole dioxides: synthesis and inhibition of Trypanosoma brucei protein farnesyltransferase. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 2217-2220.	2.2	28
112	Leishmania major activates IL-1Î± expression in macrophages through a MyD88-dependent pathway. Microbes and Infection, 2002, 4, 763-771.	1.9	70
113	Trypanosome and Animal Lanosterol Synthases Use Different Catalytic Motifs. Organic Letters, 2001, 3, 1957-1960.	4.6	39
114	Adenosine Analogues as Selective Inhibitors of Glyceraldehyde-3-phosphate Dehydrogenase ofTrypanosomatidaevia Structure-Based Drug Design. Journal of Medicinal Chemistry, 2001, 44, 2080-2093.	6.4	115
115	Cloning and functional characterization of a Trypanosoma brucei lanosterol 14Î±-demethylase gene. Molecular and Biochemical Parasitology, 2001, 117, 115-117.	1.1	6
116	TcRho1, a Farnesylated Rho Family Homologue fromTrypanosoma cruzi. Journal of Biological Chemistry, 2001, 276, 29711-29718.	3.4	31
117	Potent Anti- Trypanosoma cruzi Activities of Oxidosqualene Cyclase Inhibitors. Antimicrobial Agents and Chemotherapy, 2001, 45, 1210-1215.	3.2	72
118	Cloning, Heterologous Expression, and Distinct Substrate Specificity of Protein Farnesyltransferase from Trypanosoma brucei. Journal of Biological Chemistry, 2000, 275, 21870-21876.	3.4	55
119	Cloning and heterologous expression of the Trypanosoma brucei lanosterol synthase gene. Molecular and Biochemical Parasitology, 2000, 110, 399-403.	1.1	25
120	Adenosine Analogues as Inhibitors of Trypanosoma brucei Phosphoglycerate Kinase:â€‰ Elucidation of a Novel Binding Mode for a 2-Amino-N6-Substituted Adenosine. Journal of Medicinal Chemistry, 2000, 43, 4135-4150.	6.4	70
121	Detection of LiveTrypanosoma cruziin Tissues of Infected Mice by Using Histochemical Stain for Î²-Galactosidase. Infection and Immunity, 1999, 67, 403-409.	2.2	70
122	The effects of protein farnesyltransferase inhibitors on trypanosomatids: inhibition of protein farnesylation and cell growth. Molecular and Biochemical Parasitology, 1998, 94, 87-97.	1.1	85
123	Protein Farnesyltransferase from Trypanosoma brucei. Journal of Biological Chemistry, 1998, 273, 26497-26505.	3.4	58
124	Induction of Resistance to Azole Drugs in Trypanosoma cruzi. Antimicrobial Agents and Chemotherapy, 1998, 42, 3245-3250.	3.2	68
125	Trypanosoma cruzi:Use of Herpes Simplex Virusâ€“Thymidine Kinase as a Negative Selectable Marker. Experimental Parasitology, 1997, 86, 171-180.	1.2	10
126	Trypanosoma cruzi infection does not impair major histocompatibility complex class I presentation of antigen to cytotoxic T lymphocytes. European Journal of Immunology, 1997, 27, 2541-2548.	2.9	17

#	Article	IF	Citations
127	Trypanosoma cruzi:Expression of Interleukin-2 Utilizing both Supercoiled Plasmids and Linear DNAs. Experimental Parasitology, 1996, 83, 159-163.	1.2	12
128	Expression of mammalian cytokines by Trypanosoma cruzi indicates unique signal sequence requirements and processing. Molecular and Biochemical Parasitology, 1995, 75, 25-31.	1.1	22
129	Hypertension Following Erythropoietin Therapy in Anemic Hemodialysis Patients. American Journal of Hypertension, 1990, 3, 947-955.	2.0	94
130	Centrally Administered Inhibitors of the Generation and Action of Angiotensin II Do Not Attenuate the Increase in ACTH Secretion Produced by Ether Stress in Rats. Neuroendocrinology, 1986, 42, 97-101.	2.5	18
131	Immunological Aspects of Cardiac Disease. , 0, , 199-230.		0